PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European ...

Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Elafibranor Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides ...

Please provide your email address to receive an email when new articles are posted on . More patients on elafibranor compared with placebo achieved biochemical response, with a 47% treatment benefit.

Please provide your email address to receive an email when new articles are posted on . More than half of patients with primary biliary cholangitis who received elafibranor 80 mg achieved a ...

The evaluation committee considered evidence submitted by Ipsen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

Findings from a phase 3 study showed significant improvements in biomarkers of disease progression with elafibranor vs placebo. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Elafibranor was granted marketing authorisation for the treatment of ...

Elafibranor, a dual peroxisome proliferator-activated receptor (PPAR) alpha and delta agonist, appears to be a safe and effective treatment of primary biliary cholangitis, according to a new clinical ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...